Please wait a minute...
European Journal of Gynaecological Oncology  2018, Vol. 39 Issue (2): 199-204    DOI: 10.12892/ejgo3689.2018
Original Research Previous articles | Next articles
Role of adiponectin and leptin in non-diabetic, non-obese patients with endometrial cancer
T. Ueno1, H. Yabushita1, *(), K. Iwasaki1, A. Wakatsuki1
1 Department of Obstetrics and Gynecology, Aichi Medical University, School of Medicine, Nagakute, Japan
Download:  PDF(381KB)  ( 107 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Objective: To clarify the roles of adiponectin and leptin in endometrial cancer, this study examined serum concentrations of adiponectin and leptin, intra-tumor expression of two adiponectin receptors (AdipoR-1 and AdipoR-2) and the leptin receptor (ObR), and analyzed their relationship to clinicopathological parameters in non-diabetic, non-obese patients with endometrial cancer. Materials and Methods: Samples were obtained from 50 patients with endometrial cancer with fasting blood glucose levels < 120 mg/dl and body mass indices < 30. Serum concentrations of adiponectin, high-molecular weight (HMW) adiponectin, and leptin were measured by immunoassays. Expression of AdipoR-1, AdipoR-2, and ObR in tumor tissue was examined by immunohistochemical staining. Results: In endometrial cancer, serum concentrations of adiponectin were higher in patients with G1 or G2 tumors and in patients without lymphovascular space involvement. In 32 patients with AdipoR-1-positive tumors, serum concentrations of adiponectin, HMW adiponectin, and leptin did not differ by any pathological parameter. In contrast, in 18 patients with AdipoR-1-negative tumors, serum adiponectin concentrations were higher in patients with G1 or G2 tumors and in patients without lymphovascular space involvement. High histological grade, positive peritoneal cytology, lymphovascular space involvement, negative AdipoR-1 expression, and lower serum adiponectin levels were associated with poor disease-free survival by univariate regression analysis. In patients with AdipoR-1-negative tumors, disease-free survival was shorter in cases with serum adiponectin concentrations < 11 μg/ml. Conclusion: Decreased serum adiponectin concentrations combined with the absence of AdipoR-1 expression in tumors are associated with high-grade tumor, lymphovascular space involvement, and poor prognosis in patients with endometrial cancer.
Key words:  Endometrial cancer      Adiponectin      Leptin      Adiponectin receptor     
Published:  10 April 2018     
*Corresponding Author(s):  H. YABUSHITA     E-mail:  yab@aichi-med-u.ac.jp

Cite this article: 

T. Ueno, H. Yabushita, K. Iwasaki, A. Wakatsuki. Role of adiponectin and leptin in non-diabetic, non-obese patients with endometrial cancer. European Journal of Gynaecological Oncology, 2018, 39(2): 199-204.

URL: 

https://ejgo.imrpress.com/EN/10.12892/ejgo3689.2018     OR     https://ejgo.imrpress.com/EN/Y2018/V39/I2/199

[1] Burak Tatar. Risk of nodal metastasis associated with lymphovascular space invasion in endometrial cancer[J]. European Journal of Gynaecological Oncology, 2021, 42(5): 850-854.
[2] Jaswinder Chalia, Musse Hussein, Mariya Farooqui, Jordan Mattson, Sally A. Mullany, Molly E. Klein, Boris Winterhoff, Mahmoud A. Khalifa. Concurrent immunohistochemical testing of L1CAM and MMR proteins adds value in risk stratification of endometrial cancer: a proof of concept[J]. European Journal of Gynaecological Oncology, 2021, 42(5): 887-892.
[3] Felix Chan, Cherynne Yuin Mun Johansson. Single-site robotic-assisted hysterectomy and sentinel lymph node mapping for low-risk endometrial cancer: surgical technique and preliminary outcomes[J]. European Journal of Gynaecological Oncology, 2021, 42(5): 966-972.
[4] Englert-Golon Monika, Słopień Radosław, Smolarek Natalia, Burchardt Bartosz, Sajdak Stefan. Synchronous ovarian, endometrial and cervical cancer—case report[J]. European Journal of Gynaecological Oncology, 2021, 42(5): 1093-1094.
[5] Laura Baquedano Mainar, Javier Navarro Sierra, Leticia Alvarez Sarrado, Yasmina José Gutiérrez, Marta Lamarca Ballestero, Patricia Rubio Cuesta, Ana C. Ruiz Peña, Andrea Espiau Romera. Clinical and demographic factors in endometrial and ovary carcinoma: synchronous carcinoma vs stage IIIA endometrial carcinoma[J]. European Journal of Gynaecological Oncology, 2021, 42(4): 643-648.
[6] Reem D. Mahmood, Robert D. Morgan, Tine Descamps, Claire Mitchell, Jurjees Hasan, Nerissa Mescallado, Lisa Barraclough, Kate Haslett, Jacqueline Livsey, Emma J. Crosbie, Richard J. Edmondson, Gordon C. Jayson, Andrew R. Clamp. Sequential chemotherapy-radiotherapy as adjuvant treatment of high-risk endometrial carcinoma: a retrospective review of the Manchester experience[J]. European Journal of Gynaecological Oncology, 2021, 42(4): 673-681.
[7] Woraphot Chaowawanit, Vicki Campbell, Emily Wilson, Naven Chetty, Lewis Perrin, Nisha Jagasia, Sinead Barry. Retrospective review of sentinel lymph node mapping in endometrial cancer using indocyanine green and near infra-red fluorescence imaging during minimally invasive surgery[J]. European Journal of Gynaecological Oncology, 2021, 42(4): 694-702.
[8] Hao Lin, Hung-Chun Fu, Fu-Tsai Kung, Yu-Jen Chen, Chan-Chao Chang Chien, Chen-Hsuan Wu, Ching-Chou Tsai, Yu-Che Ou. A comparison of laparoscopic and open surgery for early stage endometrial cancer with analysis of prognostic factors: a propensity score matching study[J]. European Journal of Gynaecological Oncology, 2021, 42(4): 703-710.
[9] Tomoko Sakamoto Taniguchi, Shinichi Komiyama, Masaru Nagashima, Mineto Morita. Characteristics of microsatellite instability-high gynecologic cancer and efficacy of pembrolizumab: a single-institution experience[J]. European Journal of Gynaecological Oncology, 2021, 42(4): 752-756.
[10] Erdem Cubukcu, Ahmet Bilgehan Sahin, Fatma Oz Atalay, Birol Ocak, Mine Ozsen, Candan Demiroz Abakay, Kemal Ozerkan, Ulviyya Hasanzade, Merve Mesohorli, Adem Deligonul, Hakan Ozan, Turkkan Evrensel. The Ki-67 index and neutrophile-lymphocyte ratio are prognostic factors in patients with low-risk endometrial cancer[J]. European Journal of Gynaecological Oncology, 2021, 42(4): 775-781.
[11] Nikolaos Giannakopoulos, Ivana Virijevic, Merit Kullinger. Isolated vulvar metastasis after robot-assisted laparoscopic hysterectomy for low grade, early stage endometrial cancer: a case report and review of the literature[J]. European Journal of Gynaecological Oncology, 2021, 42(3): 418-424.
[12] Shahzarul Fazril Lin, Zainab Yahaya, Nuraini Ramli, Habibah Abdul Hamid. Synchronous endometrial and ovarian carcinoma (SEOC): case series and literature review[J]. European Journal of Gynaecological Oncology, 2021, 42(3): 434-440.
[13] Mehmet Sait Bakır, Özer Birge, Ceyda Karadag, Selen Doğan, Hasan Aykut Tuncer, Tayup Simsek. Clinicopathological risk factors and survival analysis of ovarian cancer with synchronous endometrial cancer diagnosed after surgery[J]. European Journal of Gynaecological Oncology, 2021, 42(3): 499-505.
[14] Sahin Lacin, Gozde Elif Tasar, Alp Usubutun, Zafer Arık, Deniz Yüce, Mehmet Çoşkun Salman, Ayşe Kars. The prognostic significance of microsatellite status and its relationship with tumor-infiltrating lymphocyte in endometrial cancer[J]. European Journal of Gynaecological Oncology, 2021, 42(3): 541-547.
[15] Laura M. Harbin, Laurel K. Berry, Amy E. Wahlquist, Joshua Richmond, Whitney S. Graybill, Matthew F. Kohler, William T. Creasman. Tumor proximity to serosal surface as an independent prognostic factor in FIGO stage 1 endometrial cancer[J]. European Journal of Gynaecological Oncology, 2021, 42(3): 574-579.
No Suggested Reading articles found!